Plaque psoriasis, a chronic skin condition, has seen various advancements in treatment options as of 2023.

New Biological Treatments

• **Ilumya (tildrakizumab)**: Interleukin-23 inhibitor showing significant efficacy in long-term studies.
• **Skyrizi (risankizumab)**: Highly effective in achieving complete skin clearance in clinical trials.
• **Cibinqo (abrocitinib)**: A JAK inhibitor, recently gaining traction for its oral administration option.

Topical Treatments

• **Lumos Pharma’s LUM-001**: Targeted for localized plaque psoriasis treatment with minimal side effects.
• **New steroid formulations**: Advanced formulations for potency and efficacy.

Systemic Therapies

• **Rinvoq (upadacitinib)**: Another promising JAK inhibitor with potential for treatment-resistant cases.
• **Biologic escalations**: For patients not responding to conventional treatments.

Emerging Therapies and Clinical Trials

• **Gene therapy trials**: Some studies are exploring gene editing techniques for long-term remission.
• **Combination therapies**: Research shows that using multiple types of treatments can enhance efficacy.

Comparative Efficacy of Treatments

Thoughts and Options Mind Map

• Plaque Psoriasis Treatments
  • Biologics
    • Ilumya
    • Skyrizi
    • Cibinqo
  • Topicals
    • LUM-001
    • Steroid Formulations
  • Systemics
    • Rinvoq
    • Combination Strategies
  • Emerging Options
    • Gene Therapy
    • Clinical Trials

Statistics & Projections

Future Directions

• Increased patient-centric approaches to tailor individual therapies.
• Expansion of access to newer treatments globally.
• Research on long-term impact and sustainability of therapies.

Conclusion

The landscape of plaque psoriasis treatments continues to evolve with promising advancements in biological and systemic therapies, enhancing patient care in 2023.